Oregon Public Employees Retirement Fund lifted its stake in shares of Globus Medical Inc (NYSE:GMED) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 28,896 shares of the medical device company’s stock after purchasing an additional 373 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Globus Medical were worth $1,251,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Huntington National Bank purchased a new stake in shares of Globus Medical during the 4th quarter worth approximately $38,000. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Globus Medical during the 4th quarter worth approximately $117,000. Price Capital Management Inc. purchased a new stake in shares of Globus Medical during the 3rd quarter worth approximately $131,000. Penserra Capital Management LLC purchased a new stake in shares of Globus Medical during the 3rd quarter worth approximately $161,000. Finally, Quantamental Technologies LLC purchased a new stake in shares of Globus Medical during the 4th quarter worth approximately $162,000. Institutional investors own 66.71% of the company’s stock.
NYSE:GMED traded down $0.08 during trading hours on Tuesday, hitting $45.39. The stock had a trading volume of 7,179 shares, compared to its average volume of 830,186. Globus Medical Inc has a one year low of $38.01 and a one year high of $57.83. The company has a market cap of $4.50 billion, a price-to-earnings ratio of 34.65, a PEG ratio of 2.11 and a beta of 0.82.
Several equities research analysts have recently issued reports on GMED shares. Cantor Fitzgerald set a $60.00 price target on shares of Globus Medical and gave the stock a “buy” rating in a research note on Friday, January 18th. UBS Group assumed coverage on shares of Globus Medical in a research note on Wednesday, November 28th. They issued a “neutral” rating and a $55.00 price objective for the company. Zacks Investment Research upgraded shares of Globus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, October 16th. ValuEngine lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 28th. Finally, Piper Jaffray Companies lifted their price objective on shares of Globus Medical to $62.00 and gave the company an “overweight” rating in a research note on Friday, November 9th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Globus Medical currently has an average rating of “Hold” and a consensus price target of $56.08.
WARNING: “Globus Medical Inc (GMED) Shares Bought by Oregon Public Employees Retirement Fund” was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.thelincolnianonline.com/2019/02/12/globus-medical-inc-gmed-shares-bought-by-oregon-public-employees-retirement-fund.html.
Globus Medical Company Profile
Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address an array of spinal pathologies, anatomies, and surgical approaches. Its fusion products include a range of implant and surgical approach options to treat degenerative, deformity, tumor, and trauma conditions along the spine from the occiput to the sacrum.
Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical Inc (NYSE:GMED).
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.